DPP4, dipeptidyl peptidase 4, 1803

N. diseases: 451; N. variants: 13
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0023508
Disease: White Blood Cell Count procedure
White Blood Cell Count procedure 		0.100 GeneticVariation phenotype GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
CUI: C0205682
Disease: Waist-Hip Ratio
Waist-Hip Ratio 		0.100 GeneticVariation phenotype GWASCAT Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. 30239722 2019
CUI: C0042870
Disease: Vitamin D Deficiency
Vitamin D Deficiency 		0.010 AlteredExpression disease BEFREE Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trial. 28376103 2017
CUI: C0042769
Disease: Virus Diseases
Virus Diseases 		0.010 AlteredExpression group BEFREE Experiments to identify cell determinants involved in HIV-1 tropism revealed a specific decrease in the expression of the T-cell activation antigen CD26 after monocytotropic (M-tropic) but not T-cell line-tropic (T-tropic) virus infection of the PM1 T-cell line. 7585218 1995
CUI: C0042571
Disease: Vertigo
Vertigo 		0.010 Biomarker phenotype BEFREE As a new class of antidiabetic drug, incretin-based therapies, which include dipeptidyl peptidase-4 inhibitors (DPP-4Is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have raised concerns about symptoms of withdrawal in patients with type 2 diabetes mellitus (T2DM), such as dizziness and headache. 31788342 2019
CUI: C1861172
Disease: Venous Thromboembolism
Venous Thromboembolism 		0.010 Biomarker phenotype BEFREE The system revealed a strong new signal with dipeptidylpeptidase-4 inhibitors and venous thromboembolism. 29185236 2018
CUI: C2004435
Disease: Vascular insufficiency of intestine
Vascular insufficiency of intestine 		0.010 Biomarker disease BEFREE DPP-4 enzyme deficiency protects kidney from acute ischemia-reperfusion injury: role for remote intermittent bowel ischemia-reperfusion preconditioning. 28903385 2017
CUI: C0947751
Disease: Vascular inflammations
Vascular inflammations 		0.030 Biomarker phenotype BEFREE DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs. 31134095 2019
CUI: C0947751
Disease: Vascular inflammations
Vascular inflammations 		0.030 AlteredExpression phenotype BEFREE Elevated dipeptidyl peptidase-4 (DPP-4) activity, endoglin and glycogen synthase kinase-3 (GSK-3) has also been implicated in the development of insulin resistance (IR) and/or vascular inflammation. 29677638 2018
CUI: C0947751
Disease: Vascular inflammations
Vascular inflammations 		0.030 Biomarker phenotype BEFREE DPP-4 inhibition can improve vascular aging in stressed mice, possibly by improving oxidative stress production and vascular inflammation. 31586451 2019
CUI: C0042373
Disease: Vascular Diseases
Vascular Diseases 		0.010 Biomarker group BEFREE Dipeptidyl peptidase IV inhibitors as novel regulators of vascular disease. 28697993 2017
CUI: C0342649
Disease: Vascular calcification
Vascular calcification 		0.010 Biomarker phenotype BEFREE Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells. 28686724 2017
CUI: C2145472
Disease: Urothelial Carcinoma
Urothelial Carcinoma 		0.010 AlteredExpression disease BEFREE The clinical significance of DPP4 expression was validated in our large cohort consists of 635 UCs from upper urinary tract and urinary bladder. 27936466 2017
CUI: C0042029
Disease: Urinary tract infection
Urinary tract infection 		0.030 Biomarker group BEFREE We compared the incidence of genital mycotic infection or UTI within 30 days between new users of an SGLT2 inhibitor and of a dipeptidyl-peptidase-4 (DPP4) inhibitor. 31264755 2019
CUI: C0042029
Disease: Urinary tract infection
Urinary tract infection 		0.030 GeneticVariation group BEFREE The use of DPP-4 inhibitors was associated with an increased risk of UTI (adjusted IRR 1.23, 95% CI [1.04-1.45]). 29851174 2018
CUI: C0042029
Disease: Urinary tract infection
Urinary tract infection 		0.030 GeneticVariation group BEFREE To assess whether patients initiating use of SGLT-2 inhibitors were at increased risk for severe UTI events compared with those initiating use of dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like peptide-1 receptor (GLP-1) agonists. 31357213 2019
CUI: C0041956
Disease: Ureteral obstruction
Ureteral obstruction 		0.010 Biomarker phenotype BEFREE We examined the therapeutic effects of DPP-4 inhibition in mice with unilateral ureteral obstruction (UUO), a nondiabetic model of progressive renal fibrosis. 28118775 2017
CUI: C0041912
Disease: Upper Respiratory Infections
Upper Respiratory Infections 		0.010 Biomarker group BEFREE Except for hypoglycemia and upper respiratory tract infection (URTI), there are no statistical significance on incidence of adverse events and the body weight when DPP4-I are compared with each other or with placebo. 30242726 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis 		0.010 GeneticVariation disease BEFREE All controlled clinical trials and observational studies of DPP-4 inhibitors that reported events of IBD, Crohn's disease (CD), ulcerative colitis (UC) or colitis and had a duration ≥52 weeks were included. 30700100 2019
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.080 Biomarker phenotype BEFREE We conclude that APN/CD13-associated down-regulation of NDRG-1, ME491/CD63, and DPIV/CD26 in thyroid carcinoma cells is an important step of tumor progression to more malignant phenotypes, and we underline the important role of APN/CD13 as mediator in a multimolecular process regulating cell migration. 14679016 2003
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.080 AlteredExpression phenotype BEFREE In the present study, we investigated the correlation between DPPIV expression and tumor progression in endometrial carcinoma (EC). 28060721 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.080 Biomarker phenotype BEFREE Recent studies suggested that DPP4 plays an important role in tumour progression in several human malignancies. 26267432 2015
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.080 AlteredExpression phenotype BEFREE Moreover, HFD-induced DPP4 activity facilitated angiogenesis and cancer cell metastasis in vitro and in vivo, and vildagliptin prevented tumor progression by mediating the pro-angiogenic role of chemokine ligand 2 (CCL2). 29409972 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.080 Biomarker phenotype BEFREE Recent studies have suggested that DPPIV plays an important role in tumor progression in several human malignancies. 19917055 2010
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.080 Biomarker phenotype BEFREE Several recent studies have shown that DPPIV affects tumor progression in several human malignancies. 16054016 2005